Biofrontera Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 17% revenue growth, gross margin expansion to 80%, and near-zero cash burn, reflecting the benefits of a new cost structure and strong commercial execution. Clinical pipeline advanced with FDA sNDA acceptance for SBCC and positive data in AK and acne.
-
Biofrontera and LSL Pharma Group presented at the Lytham Partners 2026 Investor Healthcare Summit, outlining robust revenue growth, margin expansion, and strategic initiatives. Both companies are leveraging acquisitions, product innovation, and market expansion to drive future performance.
Fiscal Year 2025
-
Record 2025 revenues and Q4 profitability were driven by strong Ameluz sales, a transformative asset acquisition, and a new cost structure. Clinical pipeline advances and expanded IP position set the stage for margin expansion and growth in 2026.
-
Q3 2025 revenues declined 22% year-over-year due to prior-year buying patterns, but normalization and strong Q4 growth are expected. Gross margins improved from a new royalty model, and cash flow breakeven is targeted for 2026, supported by recent financing and asset divestiture.
-
Photodynamic therapy platform Ameluz targets a $500M+ AK market with strong efficacy and expanding indications. Recent vertical integration and IP acquisition are driving margin improvements, with break-even projected in 2026. Key milestones include label expansion for cancer and acne.
-
Record Q2 and H1 2025 results driven by Ameluz sales and expanded lamp placements, with revenues up 12% year-over-year and improved gross margins expected due to a new royalty model. Legal costs spiked in Q2 but are set to normalize, and key clinical trial data is anticipated in Q4 2025.
-
Q1 2025 saw 9% revenue growth to $8.6M, improved gross margin, and a reduced net loss of $4.2M. Key milestones included new Ameluz patent protection, label expansion trials, and strong sales of the XL lamp. Cash declined to $1.8M, with break-even targeted soon.
Fiscal Year 2024
-
Record 2024 sales of $37.3M marked a 9.5% increase, driven by new product launches, FDA approvals, and improved transfer pricing. Net loss narrowed, cash position strengthened, and 2025 is expected to see further growth and margin improvement.
-
Q3 and YTD 2024 saw revenue growth, cost reductions, and key FDA label expansion. Delayed Q3 shipments and new device sales set up a strong Q4, with cash flow break-even targeted for late 2025. Clinical trials and strategic asset moves support future growth.
-
Q2 2024 saw 34% revenue growth year-over-year, improved margins, and a significant reduction in net loss. New product launches, cost controls, and a renegotiated supply agreement position the company for further growth, with key clinical data and cost savings expected in 2025.